384 related articles for article (PubMed ID: 32253184)
21. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
[TBL] [Abstract][Full Text] [Related]
23. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Baeten D; Østergaard M; Wei JC; Sieper J; Järvinen P; Tam LS; Salvarani C; Kim TH; Solinger A; Datsenko Y; Pamulapati C; Visvanathan S; Hall DB; Aslanyan S; Scholl P; Padula SJ
Ann Rheum Dis; 2018 Sep; 77(9):1295-1302. PubMed ID: 29945918
[TBL] [Abstract][Full Text] [Related]
24. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
25. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
Dubreuil M; Navarro-Compán V; Boonen A; Gaffney K; Gensler LS; de la Loge C; Vaux T; Fleurinck C; Massow U; Taieb V; Mørup MF; Deodhar A; Rudwaleit M
RMD Open; 2024 Jun; 10(2):. PubMed ID: 38834351
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
[TBL] [Abstract][Full Text] [Related]
27. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
[TBL] [Abstract][Full Text] [Related]
30. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
[TBL] [Abstract][Full Text] [Related]
32. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
[TBL] [Abstract][Full Text] [Related]
34. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
35. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
Marzo-Ortega H; Sieper J; Kivitz AJ; Blanco R; Cohen M; Pavelka K; Delicha EM; Stefanska A; Richards HB; Rohrer S
Lancet Rheumatol; 2020 Jun; 2(6):e339-e346. PubMed ID: 38273597
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Deodhar A; Sliwinska-Stanczyk P; Xu H; Baraliakos X; Gensler LS; Fleishaker D; Wang L; Wu J; Menon S; Wang C; Dina O; Fallon L; Kanik KS; van der Heijde D
Ann Rheum Dis; 2021 Aug; 80(8):1004-1013. PubMed ID: 33906853
[TBL] [Abstract][Full Text] [Related]
37. Correction:
Ann Rheum Dis; 2020 Sep; 79(9):e121. PubMed ID: 32816784
[No Abstract] [Full Text] [Related]
38. Correction:
Ann Rheum Dis; 2021 Nov; 80(11):e186. PubMed ID: 34642185
[No Abstract] [Full Text] [Related]
39. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
40. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]